株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

NTD (顧みられない熱帯病) 治療の世界市場

Global Markets for Neglected Tropical Disease Treatments

発行 BCC Research 商品コード 513410
出版日 ページ情報 英文 161 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.95円で換算しております。
Back to Top
NTD (顧みられない熱帯病) 治療の世界市場 Global Markets for Neglected Tropical Disease Treatments
出版日: 2017年06月08日 ページ情報: 英文 161 Pages
概要

世界のNTD (顧みられない熱帯病) 市場規模は、2016年から2021年にかけて14.1%のCAGR (年間複合成長率) で拡大し、2016年の14億米ドルから2021年までに26億米ドルへ達する見込みです。

当レポートでは、世界のNTD (顧みられない熱帯病) 治療市場について調査分析し、世界市場の概要、世界市場の動向分析、総市場 (TAM) に注目した感染者数・主な上市薬の現在のシェア、地域・企業別の市場シェアと将来の展望、最新の候補薬・治験・エンドポイントの考察、および主要企業のプロファイルなどをまとめています。

第1章 イントロダクション

第2章 サマリーとハイライト

第3章 疾病の概要

  • マラリア
    • 発生率・地域的分布
    • 疫学・症状
    • 社会経済的負担
    • 現在の治療法
  • リーシュマニア症
  • 住血吸虫症
  • リンパ系フィラリア症
  • シャーガス病
  • アフリカ睡眠病
  • デング熱
  • エボラ出血熱
  • ジカ熱

第4章 市場概要

  • 総市場 (TAM)
  • マラリア
    • 市場シェア:地域別
  • リーシュマニア症
  • 住血吸虫症
  • リンパ系フィラリア症
  • シャーガス病
  • アフリカ睡眠病
  • デング熱
  • エボラ出血熱
  • ジカ熱
  • 医薬品企業による寄付:薬剤へのアクセス

第5章 市場影響要因

  • 市場成長促進因子
  • 市場決定要因
  • アンメットニーズ

第6章 研究・開発

  • マラリア
    • 治験
  • リーシュマニア症
  • 住血吸虫症
  • リンパ系フィラリア症
  • シャーガス病
  • アフリカ睡眠病
  • デング熱
  • エボラ出血熱
  • ジカ熱

第7章 特許レビュー

  • マラリア
    • 特許レビュー:出願者別
    • 特許レビュー:年度別
    • 特許レビュー:国別
    • 特許レビュー:種類別
  • リーシュマニア症
  • 住血吸虫症
  • リンパ系フィラリア症
  • シャーガス病
  • アフリカ睡眠病
  • デング熱
  • エボラ出血熱
  • ジカ熱

付録:略語

BCC Researchについて

図表リスト

目次
Product Code: PHM180A

Report Highlights

The global market for neglected tropical diseases should reach $2.6 billion by 2021 from $1.4 billion in 2016 at a compound annual growth rate (CAGR) of 14.1%, from 2016 to 2021.

Report Includes:

  • An overview of the global markets for tropical disease treatments.
  • Analyses of global market trends, with data from 2015, estimates for 2016, and projections of compound annual growth rates (CAGRs) through 2021.
  • A look at the total addressable market, an indication of the number of people affected, and the current shares of key marketed therapies.
  • Representations of market shares by geography, company, and future outlook.
  • Insight on some of the newer drug candidates, clinical trials, and their end points.
  • Analyses of factors such as increases in resistance of vectors to common insecticides, increases in rapid diagnostic techniques, and no established treatment for newer conditions like Zika.
  • Profiles of major players in the industry.

Report Scope

The report focuses on newer drugs and innovations in chemical compounds, vaccines and biologicals recently launched or in development. Specifically excluded from the scope of research are vector or mosquito control approaches, strategies and products; drugs used for symptomatic treatment and not for the elimination of the virus from the host; and details on manufacturers and suppliers of nonbranded generics.

Products used for diagnosis as well as PCR techniques, kits and testing facilities are also excluded from the report.

BCC Research has categorized the markets based on regions defined by the WHO since it is the primary organization mapping disease prevalence, assisting with access to medicine and enabling partnerships. Regions include Africa, Americas, South-East Asia, Europe, Eastern Mediterranean and Western Pacific. These cover all the WHO participating countries which are described in detail in the subsequent section.

Analyst Credentials

Ms. Joshi has a master's degree in biotechnology from the Indian Institute of Technology (IIT Mumbai) and a diploma in management consulting from the Consultancy Development Centre of the Department of Scientific and Industrial Research, India. She has more than seven years experience in the fields of competitive intelligence, technology strategy, market research and patent analysis in the pharmaceutical, biotechnology and agrochemical industries. She has also worked as a technology prospecting platform manager for Monsanto.

Table of Contents

Chapter 1: Introduction

  • Study Goals and Objectives
  • Reasons for Doing this Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • Related BCC Research Reports

Chapter 2: Summary and Highlights

Chapter 3: Disease Overview

  • Malaria
    • Incidence and Geographical Distribution
    • Etiology and Symptoms
    • Socioeconomic Burden
    • Current Method of Treatment
  • Leishmaniasis
    • Incidence and Geographical Distribution
    • Etiology and Symptoms
    • Socioeconomic Burden
    • Current Method of Treatment
  • Schistosomiasis
    • Incidence and Geographical Distribution
    • Etiology and Symptoms
    • Socioeconomic Burden
    • Current Method of Treatment
  • Lymphatic Filariasis
    • Incidence and Geographical Distribution
    • Etiology and Symptoms
    • Socioeconomic Burden
    • Current Method of Treatment
  • Chagas Disease
    • Incidence and Geographical Distribution
    • Etiology and Symptoms
    • Socioeconomic Burden
    • Current Method of Treatment
  • African Trypanosomiasis
    • Incidence and Geographical Distribution
    • Etiology and Symptoms
    • Socioeconomic Burden
    • Current Method of Treatment
  • Dengue
    • Incidence and Geographical Distribution
    • Etiology and Symptoms
    • Socioeconomic Burden
    • Current Method of Treatment
  • Ebola
    • Incidence and Geographical Distribution
    • Etiology and Symptoms
    • Socioeconomic Burden
    • Current Method of Treatment
  • Zika
    • Incidence and Geographical Distribution
    • Etiology and Symptoms
    • Socioeconomic Burden
    • Current Method of Treatment

Chapter 4: Market Overview

  • Total Addressable Market
  • Malaria
    • Malaria - Market Share by Geography
  • Leishmaniasis
    • Leishmaniasis - Market Share by Geography
  • Schistosomiasis
    • Schistosomiasis - Market Share by Geography
  • Lymphatic Filariasis
    • Lymphatic Filariasis - Market Share by Geography
  • Chagas Disease
    • Chagas Disease - Market Share by Geography
  • African Trypanosomiasis
  • Dengue
    • Dengue - Market Share by Geography
  • Ebola
  • Zika
    • Zika - Market Share by Geography
  • Donations by Pharmaceutical Companies: Access to Medicines

Chapter 5: Market Influencing Factors

  • Market Drivers
    • Malaria
    • Leishmaniasis
    • Lymphatic Filariasis
    • Chagas Disease
    • African Trypanosomiasis
    • Dengue
    • Ebola
    • Zika
  • Market Deterrents
    • Malaria
    • Leishmaniasis
    • Schistosomiasis
    • Lymphatic Filariasis
    • Chagas Disease
    • African Trypanosomiasis
    • Dengue
    • Ebola
    • Zika
  • Unmet Needs
    • Malaria
    • Leishmaniasis
    • Schistosomiasis
    • Lymphatic Filariasis
    • Chagas Disease
    • African Trypanosomiasis
    • Dengue
    • Ebola
    • Zika

Chapter 6: Research and Development

  • Malaria
    • Clinical Trials in Malaria
  • Leishmaniasis
    • Clinical Trials in Leishmaniasis
  • Schistosomiasis
    • Clinical Trials in Schistosomiasis
  • Lymphatic Filariasis
    • Clinical Trials in Lymphatic Filariasis
  • Chagas Disease
    • Clinical Trials in Chagas Disease
  • African Trypanosomiasis
    • Clinical Trials in African Trypanosomiasis
  • Dengue
    • Clinical Trials in Dengue
  • Ebola
    • Clinical Trials in Ebola
  • Zika
    • Clinical Trials in Zika

Chapter 7: Patent Review

  • Malaria
    • Patent Review by Assignee
    • Patent Review by Year
    • Patent Review by Country
    • Patent Review by Type
  • Leishmaniasis
    • Patent Review by Assignee
    • Patent Review by Year
    • Patent Review by Country
    • Patent Review by Type
  • Schistosomiasis
    • Patent Review by Assignee
    • Patent Review by Year
    • Patent Review by Country
    • Patent Review by Type
  • Lymphatic Filariasis
    • Patent Review by Assignee
    • Patent Review by Year
    • Patent Review by Country
    • Patent Review by Type
  • Chagas Disease
    • Patent Review by Assignee
    • Patent Review by Year
    • Patent Review by Country
    • Patent Review by Type
  • African Trypanosomiasis
    • Patent Review by Assignee
    • Patent Review by Year
    • Patent Review by Country
    • Patent Review by Type
  • Dengue
    • Patent Review by Assignee
    • Patent Review by Year
    • Patent Review by Country
    • Patent Review by Type
  • Ebola
    • Patent Review by Assignee
    • Patent Review by Year
    • Patent Review by Country
    • Patent Review by Type
  • Zika
    • Patent Review by Assignee
    • Patent Review by Year
    • Patent Review by Country
    • Patent Review by Type

Chapter 8: Company Profiles

Appendix: Abbreviations

About BCC Research

  • About BCC Research
  • BCC Library Access
  • BCC Custom Research

List of Tables

  • Summary Table: Global Market for Neglected Tropical Diseases, by Indication, Through 2021 ($ Millions)
    • Table 1: Key Trends in Neglected Tropical Diseases
    • Table 2: Estimated Malaria Incidence (per 1,000 at Risk), 2000-2015
    • Table 3: Suspected Malaria Cases, 2010-2015 (Millions)
    • Table 4: Confirmed Malaria Cases, 2010-2015 (Millions)
    • Table 5: Estimated Spending on Malaria Treatment in Sub-Saharan Africa, 2010-2014 ($ Millions)
    • Table 6: WHO Guidelines for Treatment of Malaria
    • Table 7: Number of Cases of CL in Select High Burden Countries, 2010-2014
    • Table 8: Number of Cases of VL in Select High Burden Countries, 2010-2014
    • Table 9: Incidence of CL and VL in High Burden Countries, 2014 (Cases per 10,000 Inhabitants in Endemic Areas)
    • Table 10: Global Disease Burden of Leishmaniasis, 2015
    • Table 11: WHO Guidelines for Treatment of Leishmaniasis
    • Table 12: Number of People Treated Globally, 2010-2014 (Millions)
    • Table 13: Global Disease Burden of Schistosomiasis, 2015 (Years)
    • Table 14: Global Disease Burden of Lymphatic Filariasis, 2015 (Years)
    • Table 15: Prevalence and Incidence (Number) of Chagas Disease, 2015
    • Table 16: Global Disease Burden of Chagas Disease, 2015 (Years)
    • Table 17: Prevalence and Incidence (Number) of Chagas Disease, 2015
    • Table 18: Global Disease Burden of African Trypanosomiasis, 2015
    • Table 19: Prevalence and Incidence (Number) of Dengue Cases, 2015
    • Table 20: Reported Cases and Deaths in Ebola Outbreaks, 2007-2016
    • Table 21: Zika Burden, 2015-2016
    • Table 22: Global Addressable Market for Neglected Tropical Diseases, by Indication, Through 2021 ($ Millions)
    • Table 23: Global Addressable Market for Malaria, by Region, Through 2021 ($ Millions)
    • Table 24: Global Addressable Market for Leishmaniasis, by Region, Through 2021 ($ Millions)
    • Table 25: Global Addressable Market for Schistosomiasis, by Region, Through 2021 ($ Millions)
    • Table 26: Global Addressable Market for Lymphatic Filariasis, by Region, Through 2021 ($ Millions)
    • Table 27: Global Addressable Market for Chagas Disease, by Geography, Through 2021 ($ Millions)
    • Table 28: Global Addressable Market for Dengue, by Region, Through 2021 ($ Millions)
    • Table 29: Global Addressable Market for Zika, by Region, Through 2021 ($ Millions)
    • Table 30: Drug Donation Commitments, by WHO
    • Table 31: Malaria Development Pipeline and Recent Launches
    • Table 32: Leishmaniasis Development Pipeline and Recent Launches
    • Table 33: Schistosomiasis Development Pipeline and Recent Launches
    • Table 34: Lymphatic Filariasis Development Pipeline and Recent Launches
    • Table 35: Chagas Disease Development Pipeline and Recent Launches
    • Table 36: African Trypanosomiasis Development Pipeline and Recent Launches
    • Table 37: Dengue Development Pipeline and Recent Launches
    • Table 38: Ebola Development Pipeline and Recent Launches
    • Table 39: Zika Development Pipeline and Recent Launches
    • Table 40: Number of Patent Applications, Malaria, by Assignee
    • Table 41: Number of Patent Applications, Malaria, by Year, 2010-2015
    • Table 42: Number of Patent Applications, Malaria, by Country
    • Table 43: Number of Patent Applications, Malaria, by Type
    • Table 44: Number of Patent Applications, Leishmaniasis, by Assignee
    • Table 45: Number of Patent Applications, Leishmaniasis, by Year, 2010-2015
    • Table 46: Number of Patent Applications, Leishmaniasis, by Country
    • Table 47: Number of Patent Applications, Leishmaniasis, by Type
    • Table 48: Number of Patent Applications, Schistosomiasis, by Assignee
    • Table 49: Number of Patent Applications, Schistosomiasis, by Year, 2010-2015
    • Table 50: Number of Patent Applications, Schistosomiasis, by Country
    • Table 51: Number of Patent Applications, Schistosomiasis, by Type
    • Table 52: Number of Patent Applications, Lymphatic Filariasis, by Assignee
    • Table 53: Number of Patent Applications, Lymphatic Filariasis, by Year, 2010-2015
    • Table 54: Number of Patent Applications, Lymphatic Filariasis, by Country
    • Table 55: Number of Patent Applications, Lymphatic Filariasis, by Type
    • Table 56: Number of Patent Applications, Chagas Disease, by Assignee
    • Table 57: Number of Patent Applications, Chagas Disease, by Year, 2010-2015
    • Table 58: Number of Patent Applications, Chagas Disease, by Country
    • Table 59: Number of Patent Applications, Chagas Disease, by Type
    • Table 60: Number of Patent Applications, African Trypanosomiasis, by Assignee
    • Table 61: Number of Patent Applications, African Trypanosomiasis, by Year, 2010-2015
    • Table 62: Number of Patent Applications, African Trypanosomiasis, by Country
    • Table 63: Number of Patent Applications, African Trypanosomiasis, by Type
    • Table 64: Number of Patent Applications, Dengue, by Assignee
    • Table 65: Number of Patent Applications, Dengue, by Year, 2010-2015
    • Table 66: Number of Patent Applications, Dengue, by Country
    • Table 67: Number of Patent Applications, Dengue, by Type
    • Table 68: Number of Patent Applications, Ebola, by Assignee
    • Table 69: Number of Patent Applications, Ebola, by Year, 2010-2016
    • Table 70: Number of Patent Applications, Ebola, by Country
    • Table 71: Number of Patent Applications, Ebola, by Type
    • Table 72: Number of Patent Applications, Zika, by Assignee
    • Table 73: Number of Patent Applications, Zika, by Year, 2010-2016
    • Table 74: Number of Patent Applications, Zika, by Country
    • Table 75: Number of Patent Applications, Zika, by Type
    • Table 76: Abbreviations Used in Neglected Tropical Diseases Landscape
    • Table 77: Glossary of Terms Used in Neglected Tropical Diseases Landscape
    • Table 78: Report Sources

List of Figures

  • Summary Figure: Global Market for Neglected Tropical Diseases, by Indication, 2015-2021 ($ Millions)
    • Figure 1: Global Number of Malaria Caused Deaths, 2011-2015
    • Figure 2: Global Number of Leishmaniasis Caused Deaths, 2011-2015
    • Figure 3: Global Leishmaniasis Years of Life Lost*, 2011-2015
    • Figure 4: Global Number of Schistosomiasis Caused Deaths, 2011-2015
    • Figure 5: Global Schistosomiasis Years of Life Lost*, 2011-2015
    • Figure 6: Number of Lymphatic Filariasis Endemic Countries, by Region
    • Figure 7: Number of Chagas Disease Caused Deaths, 2011-2015
    • Figure 8: Global Chagas Disease Years of Life Lost*, 2011-2015
    • Figure 9: Number of Cases of African Trypanosomiasis, T.b. gambiense, 2011-2015
    • Figure 10: Number of Cases of African Trypanosomiasis, T.b. rhodesiense, 2011-2015
    • Figure 11: Global Number of African Trypanosomiasis Caused Deaths, 2011-2015
    • Figure 12: Global African Trypanosomiasis Years of Life Lost*, 2011-2015
    • Figure 13: Average Annual Number of Dengue Fever Cases, 1960-2007
    • Figure 14: Number of Cases in American Region, 2012-2016
    • Figure 15: Incidence Rate (per 100,000 Inhabitants) in American Region, 2012-2016
    • Figure 16: Global Number of Dengue Caused Deaths, 2011-2015
    • Figure 17: Global Dengue Caused Years of Life Lost*, 2011-2015
    • Figure 18: Outbreaks in West Africa Affected Countries (Guinea, Liberia, Sierra Leone), by Total Number of Cases, March 2014-February 2016
    • Figure 19: Outbreaks in West Africa Affected Countries (Guinea, Liberia, Sierra Leone), by Total Number of Deaths, March 2014-February 2016
    • Figure 20: Number of Countries (Y) with Number of Confirmed Zika Cases (X), by American Region, 2015-2016
    • Figure 21: Global Addressable Market for Neglected Tropical Diseases, by Indication, 2015-2021 ($ Millions)
    • Figure 22: Global Market for Malaria, by Region, 2014-2021 ($ Millions)
    • Figure 23: Global Market for Leishmaniasis, by Region, 2014-2021 ($ Millions)
    • Figure 24: Global Market for Schistosomiasis, by Region, 2014-2021 ($ Millions)
    • Figure 25: Global Market for Lymphatic Filariasis, by Region, 2014-2021 ($ Millions)
    • Figure 26: Global Market for Chagas Disease, by Geography, 2014-2021 ($ Millions)
    • Figure 27: Global Market for Dengue, by Region, 2014-2021 ($ Millions)
    • Figure 28: Global Market for Zika, by Region, 2014-2021 ($ Millions)
    • Figure 29: Clinical Trials in Malaria, by Intervention Type, January 2005-September 2016 (%)
    • Figure 30: Top 20 Sponsors/Collaborators, by Clinical Trials in Malaria, January 2005-September 2016
    • Figure 31: Clinical Trials in Leishmaniasis, by Intervention Type, January 2005-September 2016 (%)
    • Figure 32: Key Sponsors/Collaborators, Clinical Trials in Leishmaniasis, January 2005-September 2016
    • Figure 33: Clinical Trials in Schistosomiasis, by Intervention Type, January 2005-September 2016 (%)
    • Figure 34: Key Sponsors/Collaborators, Clinical Trials in Lymphatic Filariasis, January 2005-September 2016
    • Figure 35: Clinical Trials in Chagas Disease, by Intervention Type, January 2005-September 2016 (%)
    • Figure 36: Key Sponsors/Collaborators, Clinical Trials in Chagas Disease, January 2005-September 2016
    • Figure 37: Clinical Trials in Dengue, by Intervention Type, January 2005-September 2016 (%)
    • Figure 38: Key Sponsors/Collaborators, Clinical Trials in Dengue, January 2005-September 2016
    • Figure 39: Clinical Trials in Ebola, by Intervention Type, January 2005-September 2016 (%)
    • Figure 40: Key Sponsors/Collaborators, Clinical Trials in Ebola, January 2005-September 2016
    • Figure 41: Key Sponsors/Collaborators, Clinical Trials in Zika, January 2005-September 2016
    • Figure 42: Patent Share for Treatment and Preventive Medicine in Malaria, by Year (%)
    • Figure 43: Patent Share for Treatment and Preventive Medicine in Malaria, US and non-US (%)
    • Figure 44: Patent Share for Treatment and Preventive Medicine in Leishmaniasis, by Year (%)
    • Figure 45: Patent Share for Leishmaniasis, US and non-US (%)
    • Figure 46: Patent Share for Treatment and Preventive Medicine in Schistosomiasis, by Year (%)
    • Figure 47: Patent Share for Schistosomiasis, U.S. and non-U.S. (%)
    • Figure 48: Patent Share for Treatment and Preventive Medicine in Lymphatic Filariasis, by Year (%)
    • Figure 49: Patent Share for Lymphatic Filariasis, U.S. and non-U.S. (%)
    • Figure 50: Patent Share for Treatment and Preventive Medicine in Chagas Disease, by Year (%)
    • Figure 51: Patent Share for Chagas Disease, by U.S. and non-U.S. (%)
    • Figure 52: Patent Share for Treatment and Preventive Medicine in African Trypanosomiasis, by Year (%)
    • Figure 53: Patent Share for African Trypanosomiasis, US and non-US (%)
    • Figure 54: Patent Share for Treatment and Preventive Medicine in Dengue, by Year (%)
    • Figure 55: Patent Share for Dengue, U.S. and non-U.S. (%)
    • Figure 56: Patent Share for Treatment and Preventive Medicine in Ebola, by Year (%)
    • Figure 57: Patent Share for Ebola, U.S. and non-U.S. (%)
    • Figure 58: Patent Share for Treatment and Preventive Medicine in Zika, by Year (%)
    • Figure 59: Patent Share for Zika, U.S. and Non-U.S. (%)
    • Figure 60: DNDi - Research Portfolio, by Phase of Development (%)
    • Figure 61: DNDi - Research Portfolio, by Indication (%)
    • Figure 62: GlaxoSmithKline - Research Portfolio, by Phase of Development (%)
    • Figure 63: GlaxoSmithKline - Research Portfolio, by Indication (%)
    • Figure 64: MMV - Research Portfolio, by Phase of Development
    • Figure 65: MMV - Research Portfolio, by Partner (%)
Back to Top